» Articles » PMID: 33598101

Systems Biology Analysis Identifies As a Functional Marker of Tumor-infiltrating Regulatory T-cell Enabling Clinical Outcome Prediction in Lung Cancer

Overview
Specialty Biotechnology
Date 2021 Feb 18
PMID 33598101
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory T cells (Tregs) are enriched in the tumor microenvironment and play key roles in immune evasion of cancer cells. Cell surface markers specific for tumor-infiltrating Tregs (TI-Tregs) can be effectively targeted to enhance antitumor immunity and used for stratification of immunotherapy outcomes. Here, we present a systems biology approach to identify functional cell surface markers for TI-Tregs. We selected differentially expressed genes for surface proteins of TI-Tregs and compared these with other CD4 T cells using bulk RNA-sequencing data from murine lung cancer models. Thereafter, we filtered for human orthologues with conserved expression in TI-Tregs using single-cell transcriptome data from patients with non-small cell lung cancer (NSCLC). To evaluate the functional importance of expression-based markers of TI-Tregs, we utilized network-based measure of context-associated centrality in a Treg-specific coregulatory network. We identified (also known as or ), a previously reported target for enhancing antitumor immunity, among the final candidates for TI-Treg markers with high functional importance score. We found that the low expression level in Tregs was associated with enhanced overall survival rate and response to anti-PD-1 immunotherapy in patients with NSCLC, proposing that TNFRSF9 promotes immune suppressive activity of Tregs in tumor. Collectively, these results demonstrated that integrative transcriptome and network analysis can facilitate the discovery of functional markers of tumor-specific immune cells to develop novel therapeutic targets and biomarkers for boosting cancer immunotherapy.

Citing Articles

Progressive T cell exhaustion and predominance of aging tissue associated macrophages with advancing disease stage in penile squamous cell carcinoma.

Miyagi H, Yu X, Peak T, Dhillon J, Le C, Wang X Sci Rep. 2025; 15(1):7703.

PMID: 40044748 PMC: 11882776. DOI: 10.1038/s41598-025-89760-0.


Acute hypoxia modulate macrophage phenotype accompanied with transcriptome re-programming and metabolic re-modeling.

Sun B, Long Y, Xu G, Chen J, Wu G, Liu B Front Immunol. 2025; 16:1534009.

PMID: 40034701 PMC: 11872928. DOI: 10.3389/fimmu.2025.1534009.


Identification of IGF2BPs-related mRNA signature for predicting the overall survival of lung adenocarcinoma.

Xu X, Zhao W, Peng D, Sun Y, Tantai J, Zhao G Sci Rep. 2025; 15(1):5681.

PMID: 39956818 PMC: 11830784. DOI: 10.1038/s41598-025-87874-z.


CD137-expressing regulatory T cells in cancer and autoimmune diseases.

Lee K, Mei Y, Liu H, Schwarz H Mol Ther. 2024; 33(1):51-70.

PMID: 39668561 PMC: 11764688. DOI: 10.1016/j.ymthe.2024.12.010.


The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma.

Snyder M, Wang Z, Lara B, Fimbres J, Pichardo T, Mazzilli S bioRxiv. 2024; .

PMID: 39185148 PMC: 11343147. DOI: 10.1101/2024.08.12.607602.


References
1.
Karagiannis P, Iriguchi S, Kaneko S . Reprogramming away from the exhausted T cell state. Semin Immunol. 2015; 28(1):35-44. DOI: 10.1016/j.smim.2015.10.007. View

2.
Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry J . Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000; 25(1):25-9. PMC: 3037419. DOI: 10.1038/75556. View

3.
Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

4.
Ventola C . Cancer Immunotherapy, Part 1: Current Strategies and Agents. P T. 2017; 42(6):375-383. PMC: 5440098. View

5.
Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M . Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev. 2001; 182:18-32. DOI: 10.1034/j.1600-065x.2001.1820102.x. View